Entering text into the input field will update the search result below

Humanigen plunges 57% as trial for COVID-19 therapy fails

Jul. 13, 2022 6:46 AM ETHumanigen, Inc. (HGEN) StockBy: Dulan Lokuwithana, SA News Editor2 Comments

Mutating Virus Variant

wildpixel/iStock via Getty Images

  • The shares of clinical-stage biotech Humanigen, Inc. (NASDAQ:HGEN) dropped ~57% in the pre-market Wednesday after the company announced that its experimental antibody Lenzilumab failed in a trial involving hospitalized COVID-19 patients.
  • ACTIV-5/BET-B trial was a partnership between

Recommended For You

Comments (2)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

AlphaMove profile picture
This is a bankrupt company. Just do the math between their current cash, cash burn, and their liabilities due soon.
Make that 80% in RT...

About HGEN Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Humanigen, Inc.
Biocept, Inc.
ContraFect Corporation
Kintara Therapeutics, Inc.
SQZ Biotechnologies Company
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.